Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q2 2020 Earnings Presentation
13 slides from Halozyme Therapeutics's earnings presentation, Aug 10, 2020
Slide 1: Second Quarter 2020 Financial Results Call
Second Quarter 2020 Financial Results Call August 10, 2020 Confidential and Proprietary
Slide 2: Safe Harbor
Safe Harbor In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company's financial outlook for 2020) and expect
Slide 3: Phesgo: Latest FDA-approved Drug Using ENHANZE
PhesgoTM: Latest FDA-approved Drug Using ENHANZE® • PhesgoTM (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection FDA approval received on June 29 • Indicated for the treatment of eligible patients with early and metastatic HER2- positive breast cancer • Key features of PhesgoTM • Administrat
Slide 4: Subcutaneous DARZALEX Approved by Both the EC and FDA During Second Quarter
Subcutaneous DARZALEX® Approved by Both the EC and FDA During Second Quarter • Subcutaneous DARZALEX® (daratumumab) Approved by European Commission on June 4 • Indicated for the treatment of adult patients with multiple myeloma in all currently approved DARZALEX® intravenous (IV) formulation indicat
Slide 5: Five Products Commercialized in Global Markets
Five Products Commercialized in Global Markets US ROW DARZALEX FASPROTM Subcutaneous DARZALEX® (EU only) Confidential and Proprietary 5
Slide 6: Development Pipeline for ENHANZE Programs Projected to Progress and Grow
Development Pipeline for ENHANZE® Programs Projected to Progress and Grow Q2 2020 Phase 1 ongoing or Project 5 new Phase 1 complete Studies starts in 2020(1) • Efgartigimod (argenx) • Ipilimumab (BMS) • Nivolumab (BMS) • Atezolizumab (Roche) • Anti-CD73 (BMS) • Ocrelizumab (Roche) • Relatlimab (BMS)
Slide 7: Projected Milestones Drive Revenue and Free Cash Flow
Projected Milestones Drive Revenue and Free Cash Flow Milestone Revenue Projection 2019 2020 2021 2022 2018 Projection $225 - $300M 2019 Updated $350 - $450M Projection 2019 $60M Actuals Confidential and Proprietary 7
Slide 8: Capital Allocation Strategy
Capital Allocation Strategy Strong commitment to return capital to shareholders Priorities:: Potential Platform Drive ENHANZE Share Free Cash Flow Expansion via growth Repurchases M&A • Maximize value of • Board-authorized share repurchase program for $550 current collaborations million over next th
Slide 9: Second Quarter 2020 Revenue Highlights
Second Quarter 2020 Revenue Highlights1 $ U.S. in Millions (unaudited) 2Q 2020 2Q 2019 % Change Total Revenue $55.2 $39.1 41% Royalty Revenue $15.8 $18.1 (12%) Product Sales (incl. bulk rHuPH20 and ENHANZE® $6.3 $5.8 10% Drug Product Sales, and Hylenex®(2) recombinant) Collaboration Revenue $33.0 $1
Slide 10: Second Quarter 2020 Financial Highlights
Second Quarter 2020 Financial Highlights1 $ U.S. in Millions, except EPS (unaudited) 2Q 2020 2Q 2019 % Change Total Revenue $55.2 $39.1 41% Total Operating Expense $25.7 $53.1 (52%) Cost of Product Sales $5.7 $1.9 206% R&D Expense $9.0 $33.9 (74%) SG&A Expense $11.0 $17.3 (37%) Net (Loss) / Income $
Slide 11: 2020 Financial Guidance Unchanged
2020 Financial Guidance Unchanged 2020 Additional Color on Remainder of 2020 Guidance* • Royalty revenues now expected to be flat on an annual basis Net $230M – $245M • Product sales are expected to be slightly lower than FY 2019 Revenue • Collaborative revenues are expected to be higher in Q4 than
Slide 12: Value-driving Events Anticipated in 2020
Value-driving Events Anticipated in 2020 ❑ U.S. Launch of DARZALEX FASPROTM ❑ Profitability beginning in Q2 ❑ EU approval and launch of SC daratumumab ❑ Potential US approval of subcutaneous Perjeta®/Herceptin® FDC and US launch ❑ 9 new clinical trial starts ❑ Including three new Phase 3 starts Conf
Slide 13: Second Quarter 2020 Financial Results Call
Second Quarter 2020 Financial Results Call August 10, 2020 Confidential and Proprietary
Halozyme Therapeutics — Q2 2020 Earnings Presentation on 6ix